A Phase 3 interventional study of Recombinant Factor VIII (BAY81-8973) and Recombinant Factor VIII (Kogenate FS, BAY14-2222) in Blood Coagulation Disorders and Hemophilia A, sponsored by Bayer. Completed at 61 sites in 22 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 6th largest by enrollment, is one of 4 that started in 2009, is one of 4 in phase 3, and was the 9th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2009.
This study's enrollment of 74 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
57 studies in Hemophilia A by Bayer: 3 open now, 6 under way, none of them phase 3. Of 50 finished, 14 (28%) have results posted.
Among the 57 studies in Hemophilia A by Bayer, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2009, is one of 7 in phase 3, and was the 14th registered.
Bayer’s Hemophilia A studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 57 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
The study will assess the pharmacokinetics (part A) safety, tolerability, and efficacy of prophylaxis treatment (2 to 3 times a week) (part B) with BAY81-8973 over a one year period (split into two six month treatment periods). The study will compare 2 different methods (assays) for measuring the amount of study drug, the chromogenic substrate assay per European Pharmacopeia (CS/EP) with the classical assay (Chromogenic Substrate Adjusted, CS/ADJ). During one six month period patients will receive the study drug where the dose has been measured using the" (CS/EP) and during the other six months period the dose will be measured based on the Chromogenic Substrate Adjusted assay CS/ADJ)
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
This study's enrollment of 74 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Browse Hemophilia A studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Compared within Hemophilia A, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Blood Coagulation Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
Biological: Recombinant Factor VIII (BAY81-8973)
Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
Biological: Recombinant Factor VIII (BAY81-8973)
Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
Biological: Recombinant Factor VIII (BAY81-8973)
Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
Biological: Recombinant Factor VIII (BAY81-8973)
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
Part A - Area Under the Drug Concentration-time Curve (AUC)
To examine the Pharmacokinetic (PK) characteristics of BAY 81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.
Time frame: Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection. AUC calculated from time of injection to infinity.
Part A - Half-life (t 1/2)
To examine the PK characteristics of BAY81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.
Time frame: Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection.
Part B - Annualized Number of Total Bleeds
The annualized number of bleeds experienced by participants
Time frame: 12 months after randomization
Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)
The amount of Factor VIII found in blood samples taken after the injection of the study drug at the beginning of the CS/EP treatment period.
Time frame: 15-30 minutes after the injection
Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period
The annualized number of bleeds experienced by participants in each of the two treatment periods
Time frame: 6 months on each potency
Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed
The number of injections needed by participants to stop a bleed
Time frame: 6 months on each potency
Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire
A measure of how treatment with BAY81-8973 affected the daily life of participants. the scoring system has 100 points. 0 is the worst possible score. 100 is the best possible score. Positive changes from baseline indicate an improvement in quality of life and negative changes indicate a deterioration.
Time frame: Baseline and 12 months
Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire
A measure of how treatment with BAY81-8973 affected the daily life of participants. 1.0 = Best possible score, -0.594 = Worst possible score. Positive changes from baseline indicate an improvement and negative changes indicate a deterioration.
Time frame: Baseline and 12 months
Part A - Number of Participants With Inhibitory Antibody Formation
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
Time frame: Up to 6 weeks after first injection of study drug
Part B - Number of Participants With Incidence of Inhibitory Antibody Formation
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
Time frame: Up to 12 months after drug administration
Part C - Number of Participants With Incidence of Inhibitory Antibody Formation
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
Time frame: before and 3 weeks after surgery
Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
A test to analyze the formation of antibodies to HSP-70
Time frame: Up to 6 weeks after drug administration
Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
A test to analyze the formation of antibodies to HSP-70
Time frame: Up to 12 months after drug administration
Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
A test to analyze the formation of antibodies to HSP-70
Time frame: before and 3 weeks after surgery
Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
A test to ensure that participants have not developed antibodies to HCP during the study
Time frame: Up to 4 weeks after drug administration
Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
A test to ensure that participants have not developed antibodies to HCP during the study
Time frame: Up to 12 months after drug administration
Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
A test to ensure that participants have not developed antibodies to HCP during the study
Time frame: before and 3 weeks after surgery
Part B - Number of Participants With Assessment of the Hemostasis During Major Surgery
An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations
Time frame: An average of 1 month after start of treatment
Part C - Number of Participants With Assessment of the Hemostasis During Major Surgery
An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations
Time frame: at the time of surgery
Participants were recruited from specialized hemophilia treatment centers.
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 0 | 0 | 0 | 0 |
| Participants received treatment | 14 | 14 | 0 | 0 | 0 | 0 |
| Safety population | 13 | 14 | 0 | 0 | 0 | 0 |
| Completed | 14 | 14 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 0 | 0 | 0 | 0 |
| Completed | 14 | 14 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 31 | 32 | 0 | 0 |
| Participants received treatment | 0 | 0 | 30 | 32 | 0 | 0 |
| Completed | 0 | 0 | 29 | 32 | 0 | 0 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 29 | 32 | 0 | 0 |
| Completed | 0 | 0 | 29 | 32 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 55 |
| Completed | 0 | 0 | 0 | 0 | 0 | 43 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 12 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Starting another study | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 5 | 0 |
| Participants received treatment | 0 | 0 | 0 | 0 | 5 | 0 |
| Completed | 0 | 0 | 0 | 0 | 5 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII by CS/EP | Arm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 5 | 0 |
| Completed | 0 | 0 | 0 | 0 | 5 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
To examine the Pharmacokinetic (PK) characteristics of BAY 81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.
| Int.units x hours/deciliters (IU*h/dL) | Recombinant Factor VIII (BAY81-8973) - Part A | Kogenate FS (BAY14-2222) - Part A |
|---|---|---|
| Part A - Area Under the Drug Concentration-time Curve (AUC) | 1889.23 ± 36.11 | 1583.91 ± 39.89 |
To examine the PK characteristics of BAY81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.
| Hours (h) | Recombinant Factor VIII (BAY81-8973) - Part A | Kogenate FS (BAY14-2222) - Part A |
|---|---|---|
| Part A - Half-life (t 1/2) | 13.77 ± 28.00 | 12.00 ± 28.20 |
The annualized number of bleeds experienced by participants
| Bleeds | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Annualized Number of Total Bleeds | 1.03 (0.0 to 5.09) |
The amount of Factor VIII found in blood samples taken after the injection of the study drug at the beginning of the CS/EP treatment period.
| Kg/dL | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part B |
|---|---|
| Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII) | 2.50 (2.09 to 2.77) |
The annualized number of bleeds experienced by participants in each of the two treatment periods
| Bleeds | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part B | Recombinant Factor VIII (BAY81-8973) by CS/ADJ - Part B |
|---|---|---|
| Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period | 1.9 (0.0 to 4.4) | 1.9 (0.0 to 7.3) |
The number of injections needed by participants to stop a bleed
| Injections | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part B | Recombinant Factor VIII (BAY81-8973) by CS/ADJ - Part B |
|---|---|---|
| Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed | 1.0 (0 to 11) | 1.0 (1 to 48) |
A measure of how treatment with BAY81-8973 affected the daily life of participants. the scoring system has 100 points. 0 is the worst possible score. 100 is the best possible score. Positive changes from baseline indicate an improvement in quality of life and negative changes indicate a deterioration.
| Scores on a scale | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire | 2.02 (-22.9 to 26.5) |
A measure of how treatment with BAY81-8973 affected the daily life of participants. 1.0 = Best possible score, -0.594 = Worst possible score. Positive changes from baseline indicate an improvement and negative changes indicate a deterioration.
| Scores on a scale | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire | 0.00 (-0.6 to 0.5) |
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
| Participants | Recombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A |
|---|---|
| Part A - Number of Participants With Inhibitory Antibody Formation | 0 |
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
| Participants | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Number of Participants With Incidence of Inhibitory Antibody Formation | 0 |
A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973
| Participants | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|
| Part C - Number of Participants With Incidence of Inhibitory Antibody Formation | 0 |
A test to analyze the formation of antibodies to HSP-70
| Participants | Recombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A |
|---|---|
| Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70) | 0 |
A test to analyze the formation of antibodies to HSP-70
| Participants | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70) | 1 |
A test to analyze the formation of antibodies to HSP-70
| Participants | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|
| Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70) | 0 |
A test to ensure that participants have not developed antibodies to HCP during the study
| Participants | Recombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A |
|---|---|
| Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP) | 0 |
A test to ensure that participants have not developed antibodies to HCP during the study
| Participants | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP) | 0 |
A test to ensure that participants have not developed antibodies to HCP during the study
| Participants | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|
| Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP) | 0 |
An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations
| Participants | Recombinant Factor VIII (BAY81-8973) - Part B |
|---|---|
| Excellent | 1 |
| Good | 4 |
| Moderate | 0 |
| Poor | 0 |
An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations
| Participants | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|
| Excellent | 1 |
| Good | 4 |
| Moderate | 0 |
| Poor | 0 |
Collected over From the date of signing informed consent through study completion, i.e. 21 Dec 2009 to 14 Mar 2013. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Factor VIII (BAY81-8973) - Part A | — | 0/27 (0%) | 0/27 (0%) |
| Kogenate FS (BAY14-2222) - Part A | — | 0/28 (0%) | 1/28 (3.6%) |
| Recombinant Factor VIII (BAY81-8973) Part B and Extension | — | 12/62 (19.4%) | 43/62 (69.4%) |
| Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C | — | 1/7 (14.3%) | 5/7 (71.4%) |
| Event | Recombinant Factor VIII (BAY81-8973) - Part A | Kogenate FS (BAY14-2222) - Part A | Recombinant Factor VIII (BAY81-8973) Part B and Extension | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|---|---|---|
| AscitesGastrointestinal disorders | 0/27 | 0/28 | 0/62 | 1/7 |
| Chest painGeneral disorders | 0/27 | 0/28 | 2/62 | 0/7 |
| Acute myocardial infarctionCardiac disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| Spinal painGeneral disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| ErysipelasInfections and infestations | 0/27 | 0/28 | 1/62 | 0/7 |
| InjuryInjury, poisoning and procedural complications | 0/27 | 0/28 | 1/62 | 0/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| Compartment syndromeMusculoskeletal and connective tissue disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| Joint range of motion decreasedMusculoskeletal and connective tissue disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| EpilepsyNervous system disorders | 0/27 | 0/28 | 1/62 | 0/7 |
| Event | Recombinant Factor VIII (BAY81-8973) - Part A | Kogenate FS (BAY14-2222) - Part A | Recombinant Factor VIII (BAY81-8973) Part B and Extension | Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/27 | 0/28 | 4/62 | 2/7 |
| PyrexiaGeneral disorders | 0/27 | 0/28 | 1/62 | 2/7 |
| NasopharyngitisInfections and infestations | 0/27 | 0/28 | 14/62 | 0/7 |
| AnaemiaBlood and lymphatic system disorders | 0/27 | 0/28 | 0/62 | 1/7 |
| Thymus disorderBlood and lymphatic system disorders | 0/27 | 0/28 | 0/62 | 1/7 |
| DyspepsiaGastrointestinal disorders | 0/27 | 0/28 | 1/62 | 1/7 |
| NauseaGastrointestinal disorders | 0/27 | 0/28 | 4/62 | 1/7 |
| Device related infectionInfections and infestations | 0/27 | 0/28 | 0/62 | 1/7 |
| AnuriaRenal and urinary disorders | 0/27 | 0/28 | 0/62 | 1/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/27 | 0/28 | 0/62 | 1/7 |
| Age, Customized(Participants) | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C | Total |
|---|---|---|---|---|---|---|
| Part A < 18 years | 1 | 4 | NA | NA | NA | NA |
| Part A =/> 18 years | 12 | 9 | NA | NA | NA | NA |
| Part B < 18 years | NA | NA | 5 | 5 | NA | NA |
| Part B =/> 18 years | NA | NA | 25 | 27 | NA | NA |
| Part C < 18 years | NA | NA | NA | NA | 0 | NA |
| Part C =/> 18 years | NA | NA | NA | NA | 5 | NA |
| Sex/Gender, Customized(Participants) | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C | Total |
|---|---|---|---|---|---|---|
| Part A - Female | 0 | 0 | NA | NA | NA | NA |
| Part A - Male | 13 | 13 | NA | NA | NA | NA |
| Part B - Female | NA | NA | 0 | 0 | NA | NA |
| Part B - Male | NA | NA | 30 | 32 | NA | NA |
| Part C - Female | NA | NA | NA | NA | 0 | NA |
| Part C - Male | NA | NA | NA | NA | 5 | NA |
| Most recent treatment before enrolment in the study(Participants) | Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FS | Arm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973) | Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJ | Arm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EP | Arm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C | Total |
|---|---|---|---|---|---|---|
| On-demand | 4 | 3 | 4 | 8 | NA | NA |
| Prophylaxis | 10 | 11 | 26 | 24 | NA | NA |
The record gives a start of Dec 2009, a primary completion of Jun 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human